Periarticular Multimodal Drug Injections in Total Knee Arthroplasty

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether periarticular multimodal drug injection (PMDI) would provide additional benefits in patients after total knee arthroplasty (TKA) for whom contemporary pain control protocols using the continuous femoral nerve block, intra-venous patient controlled analgesia (IV-PCA)and preemptive oral medications. We hypothesized that PMDI would reduce pain level and consumption of PCA and acute pain rescuer and would provide better functional recovery and patient satisfaction. We also hypothesized that the incidence of side effects and complications of the PMDI would be similar to the No-PMDI.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Cefuroxime; Cefuroxime axetil; Epinephrine; Epinephryl borate; Ketorolac; Ketorolac Tromethamine; Morphine; Racepinephrine; Ropivacaine

Criteria

Inclusion Criteria:

• Diagnosis of primary osteoarthritis

• Scheduled for elective total knee arthroplasty

• Signed written informed consent

• Spinal anesthesia

Exclusion Criteria:

• Patients refusing consents

• inability to use the outcome assessment tools

• Contraindications to regional anesthesia

• severe cardiovascular disease

• allergy or contraindication to drugs used in this study

• pre-existing neurologic disease including psychiatric disorder

• drug abuser